This medication is given by IV infusion.
Tysabri® is a laboratory-produced monoclonal antibody. It is designed to hamper movement of potentially damaging immune cells from the bloodstream, across the “blood-brain barrier” into the brain and spinal cord.
Tysabri is approved by the U.S. Food and Drug Administration (FDA) as a monotherapy (not to be used in combination with other disease-modifying therapies) to treat relapsing forms of MS.
Click here to read the Tysabri Prescribing Information for healthcare professionals.
Click here to read the Tysabri Medication Guide for patients.
Additional information about PML:
The PML Consortium
Financial Assistance Program